ifebemtinib
An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, ifebemtinib targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.
| Synonym: | FAK1 inhibitor IN10018 protein tyrosine kinase 2 inhibitor BI 853520 protein tyrosine kinase 2 inhibitor IN10018 PTK2 inhibitor IN10018 |
|---|---|
| Code name: | BI 853520 BI-853520 BI853520 IN 10018 IN-10018 IN10018 |